SEC Form 3 · accession 0002153958-26-000002
ADARx Pharmaceuticals, Inc. · ADRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rui (NMN) Zhu
Officer — Chief Technology Officer
Period of report
Sep 24, 2026
Accepted (ET)
Sep 24, 2026 · 6:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001802369
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,511,943 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.24 | holding | — | — | — | — | Aug 19, 2030 | Common Stock | 501,996 | — | D |
| Employee Stock Option (right to buy)F2 | $0.24 | holding | — | — | — | — | Dec 6, 2030 | Common Stock | 140,305 | — | D |
| Employee Stock Option (right to buy)F3 | $0.24 | holding | — | — | — | — | Mar 18, 2031 | Common Stock | 34,138 | — | D |
| Employee Stock Option (right to buy)F4 | $0.56 | holding | — | — | — | — | May 20, 2031 | Common Stock | 362,453 | — | D |
| Employee Stock Option (right to buy)F5 | $2.29 | holding | — | — | — | — | Feb 22, 2032 | Common Stock | 34,138 | — | D |
| Employee Stock Option (right to buy)F6 | $3.26 | holding | — | — | — | — | Feb 25, 2033 | Common Stock | 42,673 | — | D |
| Employee Stock Option (right to buy)F7 | $5.84 | holding | — | — | — | — | Jan 16, 2034 | Common Stock | 51,207 | — | D |
| Employee Stock Option (right to buy)F8 | $7.05 | holding | — | — | — | — | Feb 11, 2035 | Common Stock | 42,673 | — | D |
| Employee Stock Option (right to buy)F9 | $6.31 | holding | — | — | — | — | Jan 27, 2036 | Common Stock | 68,276 | — | D |
Explanation of responses
- F1Granted to the Reporting Person on August 20, 2020. The shares subject to the option are fully vested and exercisable.
- F2Granted to the Reporting Person on December 7, 2020. The shares subject to the option are fully vested and exercisable.
- F3Granted to the Reporting Person on March 19, 2021. The shares subject to the option are fully vested and exercisable.
- F4Granted to the Reporting Person on May 21, 2021. The shares subject to the option are fully vested and exercisable.
- F5Granted to the Reporting Person on February 23, 2022. The shares subject to the option are fully vested and exercisable.
- F6Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 1, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F7Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F8Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F9Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Remarks
Exhibit 24 - Power of Attorney